Ubl leaves AdvaMed stronger than he found it

by MassDevice.com contributor Heather Thompson After a decade of leadership and 16 years of service, Stephen J. Ubl is stepping out of his role as CEO of AdvaMed. He will soon be offering his talents as a lobbyist, a sounding board, and an ambassador to the pharmaceutical industry. Ubl has accepted the position of CEO of the powerful PhRMA association. The move will mean a significant pay rise for Ubl. According to Politico, Current PhRMA CEO John Castellani earned $3.6 million in 2013, compared with Ubl’s $1.5 million. Ubl’s challenges have increased as well. It is very likely that the pharmaceutical industry is about to undergo some scrutiny on drug pricing. The Shkreli–Daraprim drug fiasco highlighted a commonplace drug pricing formula that has worked well for the drug industry in the past. But it is very likely that under the magnifying glass of social and traditional media, some changes or, at the very least, some compelling arguments will need to assuage public and governmental pressures. Ubl is certainly up to the challenge. After all, in the medical device world, Ubl has made some incredible strides. Under Ubl, AdvaMed became a powerful advocacy group. It also enjoyed a friendlier relationship with the FDA following the development of the AdvaMed Code of Ethics, among other accomplishments. “During Steve’s time at AdvaMed, the association experienced significant growth in membership, policy development capabilities as well as advocacy impact,” sa...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Business/Financial News AdvaMed Source Type: news